s-Sinai.
According to the protocol of this open-label Phase I and II trial, patients will receive a single treatment of REOLYSIN, infused over 72 hours and directed into the tumor under sophisticated guidance. Expected length of hospital stay is about five days, and patients progress will be followed for at least 12 weeks.
Oncolytics published results of preclinical studies in the June 20, 2001 issue of the Journal of the National Cancer Institute. In an animal study, mice with gliomas that were treated with a single injection of reovirus survived significantly longer than untreated mice. Complete tumor regression was found in 20 of 23 mice treated with the virus.
In laboratory studies, widespread cell killing was seen in 19 of 24 established human glioma cell lines tested. Reovirus also infected and killed all nine of nine primary glioma cultures taken from brain tumor surgical specimens. Primary refers to gliomas originating in the brain, not metastasizing from other locations.
'/>"/>
Page: 1 2 Related medicine news :1.
China Sky One Medical, Inc. Announces Its Successful Participation in the 20th International Medical Instruments and Equipment Exhibition2.
Law Offices of Howard G. Smith Announces Investigation on Behalf of Current and Former Employees of Inverness Medical Innovations, Inc. Who Invested in the Inverness Medical Innovations, Inc. Employee Savings Plan3.
Roseland Medical Center Hosts Recognition Ceremony and Open House4.
Golden State Medical Supply Selects IBM Technology to Comply With California Prescription Drug Pedigree Regulations5.
Top Policy Experts to Debate Link Between Rising Health Care Costs and Advances in Medical Technology, Wednesday, April 16, 2008, From 8:30 - 10:00 A.M., at DCs National Press Club6.
Health Care Workforce Experts Available to Comment on IOM Report on Aging Baby Boomers and Impending Medical System Crisis7.
HHS Names First Director of the Biomedical Advanced Research Development Authority8.
Northwest Hospital & Medical Center Hosts Health & Wellness Pavilion At Second Annual King 5 Healthy Living Expo9.
VisEn Medical Launches FMT(TM) 2500 - Next-Generation Fluorescence Imaging System10.
Greenway Medical Technologies Experiences Continued Growth in OB/GYN Marketplace11.
Medical Records Institute (MRI) Develops Initiative for EMRs Supporting Medicolegal Requirements